ClinicalTrials.gg
RecruitingNCT05201430RCNACUpdated Mar 4, 2022

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

A Phase 3 interventional study of FOLFOXIRI and CapeOX in Rectal Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Aug 2021, registered Dec 2021).
  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing xelox in Rectal Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. xelox · Rectal Neoplasms.

Planned enrollment
Largest of 16
300 · median 82
Started
2021
the only one that year
Phase 3
2 of 16
1 open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Fudan University

Among the 16 studies testing xelox in Rectal Neoplasms, this one has the largest planned enrollment, is the only one that started in 2021, is one of 2 in phase 3, and was the 10th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

6 of the 16 studies testing xelox in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About xelox

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing xelox in Rectal Neoplasms, or all of them as a file.
02

Study summary

This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Neoadjuvant chemotherapy
  • Locally advanced rectal cancer
  • FOLFOXIRI
  • CapeOX
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MRI evaluated of T3-4 or N+ rectal cancer;
  • diagnosed of rectal adenocarcinoma;
  • 18 to 75 years old;
  • Distance from lower margin of tumor to anus \<15 cm and suitable for anus-preserving resection;
  • Tumor amenable to radical resection;
  • Treatment-na?ve patients with no previous systemic chemotherapy, radiotherapy or local excision for treating rectal cancer;
  • Laboratory requirements conducted within 7 days of starting study treatment: ≥ 1.5×10\^9/L, count ≥ 100×10\^9 /L, ≥ 80 g/L, Serum ≤ 24umol/L, and aspartate aminotransferase ≤ 60 U/L, Serum creatinine ≤ 110 umol/L;
  • Be capable to receive a surgery;
  • No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
  • No previous systemic chemotherapy for treating colorectal cancer;
  • of more than 3 months;
  • No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of ;
  • (ECOG) performance status (PS) ≤ 1;
  • Be willing and able to understand the study and to provide written .

Exclusion criteria

Exclusion Criteria:

  • End-stage cachexia patients;
  • Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate chemotherapy or surgery;
  • carcinoma;
  • Incomplete or complete intestinal obstruction;
  • Known to be allergic to capecitabine, 5-Fu, oxaliplatin or irinotecan;
  • Pregnant or lactating women; or women who have fertility but have not taken at taken adequate measures;
  • Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric historysevere infection; active disseminated intravascular coagulation; active hepatitis, severe coagulation disorder patients;
  • History of other within the past 5 years except effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
  • Serious organic disease including but not limited to heart, kidney, brain, and lung.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    A: FOLFOXIRI

    Neoadjuvant chemotherapy with 3-4 cycles of FOLFOXIRI regimen, followed by surgery

    Drug: FOLFOXIRI

  • Experimental
    B: CapeOX

    Neoadjuvant chemotherapy with 2-3 cycles of CapeOX regimen, followed by surgery

    Drug: CapeOX

Interventions

  • DrugFOLFOXIRI

    irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)

    Also known as: 5-Fu, Oxaliplatin, Irinotecan, Surgery

  • DrugCapeOX

    Drug page: XeloxStudies of XeloxXelox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)

    Also known as: Capecitabine, Oxaliplatin, Surgery

06

What researchers measure

Primary outcomes

  1. 3-year disease free survival

    Defined as the length of time from the date of randomization until the first documented date of progression or death from any cause, whichever comes first. Compare 3-year disease free survival in patients with locally advanced rectal cancer treated with either FOLFOXIRI or CapeOX neoadjuvant chemotherapy.

    Time frame: 3 years

Secondary outcomes

  1. pathologic complete response rate

    Defined as the ratio of patients with pathologic TRG 0

    Time frame: 1 year

  2. major pathologic response rate

    Defined as the ratio of patients with pathologic TRG 0 or 1

    Time frame: 1 year

  3. objective response rate

    Defined as the ratio of patients with MRI-TRG 1, 2 or 3

    Time frame: 1 year

  4. local recurrence rate

    Defined as the ratio of patients with local recurrence within 3 years.

    Time frame: 3 years

  5. overall survival

    Defined as the length of time from randomization date until the date of death from any cause.

    Time frame: 5 years

  6. quality of life as assessed by EORTC QOL-C30

    Quality of life after neoadjuvant chemotherapy is assessed by questionaires EORTC QOL-C30 version 3

    Time frame: 3 years

  7. quality of life as assessed by EORTC QOL-CR29

    Quality of life after neoadjuvant chemotherapy is assessed by questionaires EORTC QOL-CR29.

    Time frame: 3 years

  8. adverse event

    Number of patients with adverse events and severity according to NCI CTC 5.0 after neoadjuvant chemotherapy.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Proper legal IPD will be shared when publishing articles.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Jun 2024, 34 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 34 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2021
First posted
Jan 21, 2022
StartActual
Aug 27, 2021
Primary completionEst.
Jun 2024
CompletionEst.
Jul 2027
Last update
Mar 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05201430
Lead sponsor
Fudan University
Responsible party
Ye Xu (Professor, Chief of Department of Colorectal Surgery, Fudan University) — Principal investigator
First posted
Jan 21, 2022
Start date
Aug 27, 2021
Primary completion
Jun 2024 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 4, 2022

Study contacts

Tianan Guo
Contact
11307120071@fudan.edu.cn
+86-021-64035387
Ye Xu
Contact
yexu@shmu.edu.cn
+86-021-64035387
Ye Xu
principal investigator · Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xelox

Start the discussion